|1.||Altmann, Karl-Heinz: 10 articles (05/2011 - 03/2003)|
|2.||Hoffmann, Jens: 6 articles (01/2011 - 07/2008)|
|3.||Klar, Ulrich: 6 articles (01/2011 - 07/2008)|
|4.||Gertsch, Jürg: 6 articles (01/2010 - 01/2008)|
|5.||Burris, Howard A: 5 articles (10/2012 - 03/2007)|
|6.||Tang, Li: 4 articles (04/2014 - 01/2003)|
|7.||Hammer, Stefanie: 4 articles (01/2011 - 07/2008)|
|8.||Goodin, Susan: 4 articles (10/2010 - 05/2004)|
|9.||Vahdat, Linda T: 4 articles (10/2010 - 08/2007)|
|10.||Lee, James J: 4 articles (02/2009 - 04/2006)|
02/01/2012 - "Phase I dose escalation study of KOS-1584, a novel epothilone, in patients with advanced solid tumors."
10/01/2011 - "Phase I clinical and pharmacokinetic study of UTD1, a genetically engineered epothilone analog in patients with advanced solid tumors."
07/01/2009 - "To review the pharmacologic properties of a novel class of chemotherapeutic agents, the epothilones, and to summarize findings from recent clinical trials investigating the various epothilones in cancer therapy. "
05/15/2008 - "Ongoing clinical trials will continue to define the role of the epothilones in cancer therapy."
05/15/2008 - "Preclinical studies also have demonstrated synergistic increases in tumor cell killing when the epothilones are combined with other antitumor medications. "
|2.||Breast Neoplasms (Breast Cancer)
12/01/2008 - "Ongoing research aims to define and optimize the efficacy of the epothilones in an attempt to improve the quality of life and overall survival of individuals with breast cancer."
04/01/2008 - "Clinical studies with epothilones for the treatment of metastatic breast cancer."
03/01/2008 - "Also discussed are results from clinical trials of epothilones alone and in combination in patients with breast cancer."
07/01/2007 - "This review summarizes clinical studies of epothilones in patients with metastatic breast cancer. "
03/01/2007 - "The results of these studies are eagerly awaited and it is anticipated that epothilones may become an important treatment option in patients with breast cancer."
|3.||Prostatic Neoplasms (Prostate Cancer)
08/01/2005 - "Epothilones and the next generation of phase III trials for prostate cancer."
07/01/2011 - "Epothilones in prostate cancer."
02/01/2009 - "The epothilones have demonstrated a wide range of clinical activity, including important antitumor effects, in advanced prostate cancer. "
07/01/2007 - "The epothilones have demonstrated potent antitumor activity in vitro and in experimental animal models of prostate cancer. "
07/01/2007 - "Epothilones in prostate cancer: review of clinical experience."
|4.||Ovarian Neoplasms (Ovarian Cancer)
04/01/2011 - "Epothilones in the treatment of ovarian cancer."
01/01/2015 - "Nevertheless, responses to epothilones have been observed in platinum-refractory/resistant ovarian cancer patients. "
12/01/2012 - "These results demonstrated that Gli1 played a key role in driving resistance to patupilone, suggesting that the combination of epothilones and Gli1-targeted agents could be exploited to improve outcomes in ovarian cancer patients resistant to standard treatments."
05/01/2011 - "Further, epothilones and oxaliplatin, already approved drugs for other cancer entities, show promising activity against ovarian cancer; they are even of interest as a first-line treatment option. "
11/01/2011 - "A phase II trial evaluating two schedules of sagopilone (ZK-EPO), a novel epothilone, in patients with platinum-resistant ovarian cancer."
|5.||Brain Neoplasms (Brain Tumor)
|1.||ixabepilone (BMS 247550)
|5.||epothilone B (EPO906)
|6.||desoxyepothilone B (epothilone D)
|9.||Excipients (Suspending Agents)
|1.||Drug Therapy (Chemotherapy)
|2.||Heterologous Transplantation (Xenotransplantation)